Patient-Reported Experiences of Persistent Post–COVID-19 Conditions After Hospital Discharge During the Second and Third Waves of the Pandemic in Switzerland: Cross-Sectional Questionnaire Study
JMIR Public Health and Surveillance · 2024
DOI: 10.2196/47465 ↗At a glance
Querschnittstudie in JMIR Public Health and Surveillance, 2024. Written by Nadine Tacchini-Jacquier and 4 co-authors. Institution: Development of Nursing Practices Unit, Valais Hospitals, Sion, Switzerland. Major MEDLINE topics: COVID-19, Patient Discharge, Self Report. Cited 3 times so far (Crossref); 80 references. The full text is freely available in PubMed Central.
Abstract (original language)
Background
Hospitalized patients infected with SARS-CoV-2 should recover within a few weeks. However, even those with mild versions can experience symptoms lasting 4 weeks or longer. These post–COVID-19 condition (PCC) comprise various new, returning, or ongoing symptoms that can last for months or years and cause disability. Few studies have investigated PCC using self-reports from discharged patients infected with SARS-CoV-2 to complement clinical and biomarker studies.
Objective
This study aimed to investigate self-reported, persistent PCC among patients infected with SARS-CoV-2 who were discharged during the second and third waves of the COVID-19 pandemic.
Methods
We designed, pretested, and posted an ad hoc paper questionnaire to all eligible inpatients discharged between October 2020 and April 2021. At 4 months post discharge, we collected data on PCC and scores for the Multidimensional Fatigue Inventory (MFI), the Patient Health Questionnaire-4 (PHQ-4), a Brief Memory Screening Scale (Q3PC), and a posttraumatic stress disorder scale (PCL-5). Descriptive, inferential, and multivariate linear regression statistics assessed PCC symptomatology, associations, and differences regarding sociodemographic characteristics and hospital length of stay (LOS). We examined whether our variables of interest significantly predicted MFI scores.
Results
Of the 1993 valid questionnaires returned, 245 were from discharged patients with SARS-CoV-2 (median age 71, IQR 62.7-77 years). Only 28.2% (69/245) of respondents were symptom-free after 4 months. Women had significantly more persistent PCC symptoms than men (P≤.001). Patients with a hospital LOS ≥11 days had more PCC symptoms as well (P
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Development of Nursing Practices Unit, Valais Hospitals, Sion, Switzerland.
- Social Affairs and Human Resources, Valais Hospitals, Sion, Switzerland.
- Pneumonology, Valais Hospitals, Sion, Switzerland.
- General Direction, Valais Hospitals, Sion, Switzerland.
- Department of Nursing, School of Health Sciences, University of Applied Sciences and Arts Western Switzerland (HES-SO), Sion, Switzerland.
- Valais Hospitals, Sion, Switzerland.
ORCID profiles: Nadine Tacchini-Jacquier, Sévrine Monnay, Nicolas Coquoz, Eric Bonvin, Henk Verloo
Cite
APA
Tacchini-Jacquier, N., Monnay, S., Coquoz, N., Bonvin, E., & Verloo, H. (2024). Patient-Reported Experiences of Persistent Post–COVID-19 Conditions After Hospital Discharge During the Second and Third Waves of the Pandemic in Switzerland: Cross-Sectional Questionnaire Study. JMIR Public Health and Surveillance. https://doi.org/10.2196/47465
Vancouver
Tacchini-Jacquier N, Monnay S, Coquoz N, Bonvin E, Verloo H. Patient-Reported Experiences of Persistent Post–COVID-19 Conditions After Hospital Discharge During the Second and Third Waves of the Pandemic in Switzerland: Cross-Sectional Questionnaire Study. JMIR Public Health and Surveillance. 2024. doi:10.2196/47465
BibTeX
@article{TacchiniJacquier2024,
author = {Tacchini-Jacquier, Nadine and Monnay, Sévrine and Coquoz, Nicolas and Bonvin, Eric and Verloo, Henk},
title = {Patient-Reported Experiences of Persistent Post–COVID-19 Conditions After Hospital Discharge During the Second and Third Waves of the Pandemic in Switzerland: Cross-Sectional Questionnaire Study},
journal = {JMIR Public Health and Surveillance},
year = {2024},
doi = {10.2196/47465}
}
EUVIMED